"We're continuing to explore partnership discussions with a number of local Chinese players. I think, specifically, BeiGene, of course, has a broader portfolio, has a strong oncology presence in China. And of course, we're looking forward to continuing that strong collaboration with them, but also with other strong local Chinese players as it makes sense for our portfolio."